Abstract
There are currently a number of licensed azole antifungal drugs; however; only 4 (namely, fluconazole, itraconazole, posa- conazole, and voriconazole) are used frequently in a clinical setting for prophylaxis or treatment of systemic fungal infections. In this article, we review the pharmacokinetic interactions of these azole antifungal drugs with other coadministered agents. We describe these (2-way) interactions and the extent to which metabolic pathways and/or other supposed mechanisms are involved in these interactions. This article provides an overview of all published drug-drug interactions in humans (either healthy volunteers or patients), and on the basis of these findings, we have developed recommendations for managing the specific interactions. © 2009 by the Infectious Diseases Society of America. All rights reserved.
Cite
CITATION STYLE
Brüggemann, R. J. M., Alffenaar, J. W. C., Blijlevens, N. M. A., Billaud, E. M., Kosterink, J. G. W., Verweij, P. E., & Burger, D. M. (2009, May 15). Clinical relevance of the pharmacokinetic interactions of azole antifungal drugs with other coadministered agents. Clinical Infectious Diseases. https://doi.org/10.1086/598327
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.